Ocuphire Pharma: Funding, Investors & Team (Oct 2026)
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Ocuphire Pharma has raised $35.0M across 2 funding rounds on record, the most recent an undisclosed round of $20.0M announced in Mar 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ocuphire Pharma Company Profile and Key Stats
Latest funding round on record: Mar 2025.
Ocuphire Pharma Funding Rounds
Ocuphire Pharma raised $15.0M in an undisclosed round announced in Jun 2021.
3.8 years later, an undisclosed round of $20.0M was announced in Mar 2025.
Ocuphire Pharma Founders and Leadership Team
Contact details for the Ocuphire Pharma team: 1 of 2 have an email address on file.
Start 14-day free trial →Ocuphire Pharma Funding Compared to Other Biotechnology Startups
Ocuphire Pharma's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ocuphire Pharma in Biotechnology and Farmington Hills
Companies Similar to Ocuphire Pharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Ocuphire Pharma Funding FAQs
What does Ocuphire Pharma do?
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night vision disturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
How much funding has Ocuphire Pharma raised?
Ocuphire Pharma has raised $35.0M across 2 rounds on record. The most recent is an undisclosed round of $20.0M announced in Mar 2025.
When did Ocuphire Pharma last raise funding?
Ocuphire Pharma's most recent funding round on record is an undisclosed round of $20.0M, announced in Mar 2025.
Who founded Ocuphire Pharma?
FundedIQ lists Alan Meyer (Founder) at Ocuphire Pharma.
Who is the CEO of Ocuphire Pharma?
Mina Sooch is listed as CEO at Ocuphire Pharma.
Where is Ocuphire Pharma headquartered?
Ocuphire Pharma is based in Farmington Hills, Michigan, United States.
How many employees does Ocuphire Pharma have?
Ocuphire Pharma is in the 11-50 employee band.
How does Ocuphire Pharma's funding compare to other Biotechnology startups?
Ocuphire Pharma's latest round of $20.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Ocuphire Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ocuphire Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.